Alpha-9 Oncology
PrivateLast Round
Series C
Oct 23, 2024
Total Funding Raised
$261M
Company Overview
Alpha-9 Oncology is a biotechnology company that develops targeted radiopharmaceuticals for the diagnosis and treatment of solid and hematologic malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alpha-9 Oncology Comparables
Compare Alpha-9 Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abdera Therapeutics | 90% | |
| Convergent Therapeutics | 87% | |
| Ratio Therapeutics Inc. | 86% | |
Alpha-9 Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 23, 2024 | ||||
| Series B | Dec 14, 2022 | ||||
| Series A | Apr 28, 2021 |
Key People
Founding team and executive leadership
Alpha-9 Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series C |
| Longitude Capital | Series B, Series C, Series A |
| Janus Henderson Group | Series C |
| Aberdeen Group plc | Series C |
| RA Capital Management | Series C |
| Digitalis Ventures | Series C |
| abrdn Inc. | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 3, 2025
Radiopharmaceutical programs are currently in Phase 0-1 clinical trials.
- Oct 14, 2025
Paul Blanchfield named Chief Executive Officer on October 14, 2025.
Alpha-9 Oncology Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alpha-9 Oncology's valuation, stock price, and market status.